Abstract
Tuberous sclerosis complex lesions of the skin may be disfiguring to patients and can only be treated by laser or cosmetic surgery. Clarification of the molecular and structural changes involved in skin hamartomas may unravel targets for pharmacotherapy. We investigated the expression of matrix metalloproteinase (MMP) and its tissue inhibitor (TIMP) in fibrous plaques, angiofibromas, and lesion-free skin specimens from patients with tuberous sclerosis complex. Gene expression of MMPs and TIMP-1 was measured by reverse transcription polymerase chain reaction, gelatinase activity by gelatin zymography, and the content of collagenases and TIMPs by enzyme-linked immunosorbent assay. Compared with lesion-free specimens, hamartomas exhibited decreased levels of TIMPs and messenger RNA expression of TIMP-1, and increased content of MMP-1 and MMP-13 and activity of MMP-9, although gelatinase gene expression was diminished. Gene expression of MMP-15 and MMP-17 was not affected but was diminished for MMP-14. The significant variations of the above extracellular matrix molecules between lesion-free specimens and tuberous sclerosis complex hamartomas overall favors a collagenous protein-degrading microenvironment in affected skin, and argu...Continue Reading
References
Jan 1, 1982·Brain & Development·H KonomiY Nagai
Dec 1, 1982·The British Journal of Dermatology·A OikarinenL Peltonen
Aug 1, 1995·European Journal of Biochemistry·S TriebelH Tschesche
Jun 1, 1995·The Biochemical Journal·Y ItohH Nagase
Aug 8, 1997·Science·M van SlegtenhorstD J Kwiatkowski
Apr 29, 1998·Matrix Biology : Journal of the International Society for Matrix Biology·T A GiambernardiR J Klebe
Feb 9, 1999·Molecular Biology of the Cell·I Sehgal, T C Thompson
Jun 18, 1999·Matrix Biology : Journal of the International Society for Matrix Biology·G M GrantR J Klebe
Oct 26, 1999·Neurology·P B Crino, E P Henske
Dec 12, 2000·American Journal of Human Genetics·S L DaboraD J Kwiatkowski
May 12, 2001·Cell·N TaponI K Hariharan
May 26, 2001·The Journal of Clinical Investigation·V LemaîtreJ D'Armiento
Jun 9, 2001·Mutation Research·M HengstschlägerM Kubista
Oct 19, 2001·Journal of the American Academy of Dermatology·R C BittencourtR J Barlow
Feb 28, 2002·Journal of the American Academy of Dermatology·Jack L ArbiserSharon W Weiss
May 8, 2002·European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society·Paolo CuratoloRoberta Bombardieri
May 15, 2002·Trends in Cardiovascular Medicine·Jeanine D'Armiento
Aug 23, 2002·Experimental Dermatology·Emanuela MaioliConcetta Gardi
Apr 19, 2003·Experimental Dermatology·E Kerkelä, U Saarialho-Kere
Citations
Aug 31, 2006·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Chrysanthos SymeonidisStavros A Dimitrakos
Dec 21, 2012·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Chrysanthos SymeonidisStavros A Dimitrakos
Mar 20, 2010·Lymphatic Research and Biology·Angelo M Taveira-DaSilvaJoel Moss
Nov 30, 2007·Retina·Chrysanthos SymeonidisGeorge Karakiulakis
Oct 21, 2014·American Journal of Respiratory and Critical Care Medicine·Jianhua YaoJoel Moss
Sep 28, 2005·The Journal of Investigative Dermatology·Eleni PapakonstantinouGeorge Karakiulakis
Nov 12, 2016·Expert Opinion on Orphan Drugs·Angelo M Taveira-DaSilva, Joel Moss
Aug 12, 2010·The British Journal of Dermatology·C-H LeeK-C Yang
Sep 22, 2009·Acta Ophthalmologica·Chrysanthos SymeonidisEudoxia Diza
Aug 11, 2006·European Urology·Dionisios MitropoulosGeorge Karakiulakis
Aug 16, 2016·Clinics in Chest Medicine·Simon R JohnsonJoel Moss
Dec 11, 2008·The British Journal of Dermatology·K A GiehlG N Eckstein
May 27, 2011·Clinical Pharmacology and Therapeutics·Y PouliotA J Butte